

Supplementary Table 2. *In vitro* drug susceptibility to the first line anti TB therapy among MTB isolates during 2009-2018

	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Total	P-value
Sensitive	213 85.9%	203 89.0%	246 89.1%	255 88.5%	231 84.6%	246 86.6%	231 88.5%	219 82.3%	203 89.4%	151 80.3%	2198 86.6%	0.050
SMR	6 2.4%	5 2.2%	9 3.3%	5 1.7%	10 3.7%	4 1.4%	3 1.1%	12 4.5%	8 3.5%	3 1.6%	65 2.6%	0.113
INHR	13 5.2%	10 4.4%	5 1.8%	12 4.2%	16 5.9%	10 3.5%	8 3.1%	5 1.9%	4 1.8%	9 4.8%	92 3.6%	0.025
RIFR	0 0.0%	1 .4%	0 0.0%	1 .3%	1 .4%	2 .7%	3 1.1%	0 0.0%	0 0.0%	1 .5%	9 .4%	0.210
PZAR	2 .8%	1 .4%	8 2.9%	3 1.0%	6 2.2%	6 2.1%	6 2.3%	16 6.0%	11 4.8%	17 9.0%	76 3.0%	< 0.05
PolyR	6 2.4%	6 2.6%	2 .7%	4 1.4%	3 1.1%	6 2.1%	4 1.5%	7 2.6%	0 0.0%	3 1.6%	41 1.6%	0.158
MDR	8 3.2%	2 .9%	6 2.2%	8 2.8%	6 2.2%	10 3.5%	6 2.3%	7 2.6%	1 .4%	4 2.1%	58 2.3%	0.248
Total	248	228	276	288	273	284	261	266	227	188	2539	

*SMR (Streptomycin-resistant), INHR (Isoniazid-resistant), RIFR (Rifampicin-resistant), PZAR (Pyrazinamide-resistant), PolyR (Poly-resistant), MDR (Multi-drug-resistant), XDR (Extensively-drug-resistant)